Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | LY3537982 |
Trade Name | |
Synonyms | LY 3537982|LY-3537982 |
Drug Descriptions |
LY3537982 selectively inhibits KRAS G12C, potentially leading to growth inhibition of KRAS G12C-expressing tumor cells (Cancer Res 2021;81(13_Suppl):Abstract nr 1259). |
DrugClasses | KRAS G12C inhibitor 28 |
CAS Registry Number | NA |
NCIT ID | C181751 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Abemaciclib + LY3537982 | Abemaciclib LY3537982 | 0 | 1 |
Cetuximab + LY3537982 | Cetuximab LY3537982 | 0 | 1 |
Erlotinib + LY3537982 | Erlotinib LY3537982 | 0 | 1 |
LY3214996 + LY3537982 | LY3214996 LY3537982 | 0 | 1 |
LY3295668 + LY3537982 | LY3295668 LY3537982 | 0 | 1 |
LY3537982 | LY3537982 | 0 | 1 |
LY3537982 + Sintilimab | LY3537982 Sintilimab | 0 | 1 |